Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Single Center, Single Arm Phase II Clinical Study of TPF Combined With Immune Checkpoint Inhibitor Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma Patients

NCT06781112 is registered in ClinicalTrials.gov with Weiwei Zhang as lead sponsor.

NCT NCT06781112
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06781112 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Single Center, Single Arm Phase II Clinical Study of TPF Combined With Immune Checkpoint Inhibitor Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma Patients
Lead sponsor
Weiwei Zhang
Phase
Phase 2
Overall status
Not yet recruiting
Start date
January 20, 2025
Completion date
December 31, 2028
Enrollment
35 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

immunotherapy, nasopharyngeal carcinoma, phase ii clinical study, tpf